NovoCure Limited (NVCR)

NMS – Цена в реальном времени. Валюта: USD

18.31

+0.21 (1.16%)

При закрытии: May 12, 2026, 4:00 PM EDT

18.31

0.00 (0.00%)

После закрытия: May 12, 2026, 7:38 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

NovoCure Limited (NVCR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NovoCure Limited (NVCR)

International Markets and NovoCure (NVCR): A Deep Dive for Investors

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

Novocure Reports First Quarter 2026 Financial Results

Novocure to Report First Quarter 2026 Financial Results

NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Видео

No Data

Пресс-релизы

Novocure Reports First Quarter 2026 Financial Results

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Search stocks

NovoCure Limited (NVCR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NovoCure Limited (NVCR)

International Markets and NovoCure (NVCR): A Deep Dive for Investors

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

Novocure Reports First Quarter 2026 Financial Results

Novocure to Report First Quarter 2026 Financial Results

NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Видео

No Data

Пресс-релизы

Novocure Reports First Quarter 2026 Financial Results

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update